A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

Lignende værker

• A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
  af: Burnett, A K, et al.
  Udgivet: (2017)
• A randomized comparison of daunorubicin 90 mg/m(2) vs 60 mg/m(2) in AML induction: results from the UK NCRI AML17 trial in 1206 patients
  af: Burnett, Alan K., et al.
  Udgivet: (2015)
• Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
  af: Burnett, Alan K, et al.
  Udgivet: (2018)
• Relapsed or primary refractory AML: moving past MEC and FLAG-ida
  af: Koenig, Kristin, et al.
  Udgivet: (2020)
• Daunorubicin in acute leukaemia
  af: Souhami, R. L., et al.
  Udgivet: (1970)